Why the study?
Does bedtime dosing of valsartan improve renal and cardiovascular surrogate markers in CKD patients with a nondipping blood pressure pattern compared to awakening dosing?
Population
90 patients with chronic kidney disease, including 60 with a nondipping blood pressure pattern and 30 with a…
Comparison
Valsartan 80-320 mg administered at bedtime vs Valsartan 80-320 mg administered at awakening
Design
RCT, randomly divided into two groups
Authors
Loading...
Bedtime valsartan may improve surrogates in nondipping CKD; extends chronotherapy evidence but requires hard-outcome confirmation.
Does bedtime dosing of valsartan improve renal and cardiovascular surrogate markers in CKD patients with a nondipping blood pressure pattern compared to awakening dosing?
Bedtime administration of valsartan in CKD patients with a nondipping blood pressure pattern improves renal and cardiovascular surrogate markers compared to morning dosing.
Wang et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: